Synchron Australia

Synchron Australia is a neurotechnology company headquartered in Melbourne, developing brain-computer interface technology designed to restore communication and functional independence for people living with severe neurological conditions. The company's flagship product, the Stentrode, is a minimally invasive BCI implanted through the blood vessels of the neck rather than through open brain surgery, significantly reducing the risks associated with traditional neural implant procedures. Once positioned in a blood vessel adjacent to the motor cortex, the Stentrode records neural signals generated during motor imagery, translating thought-based intentions into digital commands. This endovascular approach represents a fundamental departure from conventional BCI design and positions Synchron as a leader in accessible, scalable neural interface technology.

Synchron has made substantial clinical progress, becoming one of the first companies in the world to receive FDA approval to conduct human trials for a permanently implanted BCI in the United States. The company has demonstrated that ALS patients implanted with the Stentrode can independently control computers, smartphones, and other digital devices using thought alone, without requiring caregiver assistance. These outcomes have been documented through peer-reviewed research and represent meaningful real-world validation of the technology's therapeutic potential. Synchron has secured Series B funding of $75 million, providing the capital foundation to expand its clinical program and accelerate the path toward regulatory approval and commercialisation.

Synchron's significance to the broader neurotechnology industry extends well beyond its own product pipeline. By proving that a minimally invasive approach to neural recording is clinically viable, the company has challenged long-held assumptions about the trade-offs between safety and signal quality in BCI design. Their work opens a potential pathway for BCIs to reach a far larger patient population than was previously considered feasible, given that many candidates are excluded from open-brain implant procedures due to health constraints. As the global race to develop practical, safe, and scalable BCIs intensifies, Synchron's Australian research operations stand as a critical contributor to shaping the clinical and regulatory standards that will define the industry's future.